Clinical trial
Imatinib Mesylate Combined With Intravitreal Ranibizumab in the Treatment of…
NCT00403156 · Vitreous -Retina- Macula Consultants of New York, Other · Withdrawn
Key facts
| NCT number | NCT00403156 |
|---|---|
| Title | Imatinib Mesylate Combined With Intravitreal Ranibizumab in the Treatment of Choroidal Neovascularization Secondary to Age-Related Macular Degeneration |
| Official title | A Phase I Study of the Inhibition of Platelet Derived Growth Factor Using Imatinib Mesylate Combined With Intravitreal Ranibizumab in the Treatment of Choroidal Neovascularization Secondary to Age-Related Macular Degeneration |
| Lead sponsor | Vitreous -Retina- Macula Consultants of New York, Other |
| Collaborators | Genentech, Inc. Industry |
| Status | Withdrawn |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Choroidal Neovascularization |
| Intervention type | Drug |
| Interventions | Imatinib Mesylate /Ranibizumab |
| Enrollment | 0 |
| Start date | Nov 1, 2006 |
| First posted | Nov 23, 2006 |
| Last update posted | Dec 31, 2015 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: